1	Antimicrobial Susceptibilities of Clinical Bacterial Isolates from Urinary Tract Infections to Fosfomycin
2	and Comparator Antibiotics Determined by Agar Dilution Method and Automated Micro Broth Dilution
3	
4	¹ Jamie L Dombach, ² Nancy Smith, ² Teresa Kottiri, ¹ Alicia Schiller, ^{2,3} Edwin Kamau [#]
5	
6	¹ Department of Clinical Investigations, Tripler Army Medical Center, Honolulu, HI, USA
7	² Department of Pathology and Area Laboratory Services, Walter Reed National Military Medical Center,
8	Bethesda, MD, USA
9	³ Department of Pathology and Area Laboratory Services, Tripler Army Medical Center, Honolulu, HI, USA
10	
11	Running Title: Susceptibility of US Clinical Isolates to Fosfomycin
12	
13	#Address correspondence to Edwin.Kamau.mil@health.mil
14	Abstract word count: 333
15	Text word count:
16	
17	
18	
19	

20 ABSTRACT

21 Uncomplicated bacteremic urinary tract infections (bUTIs) are common, often caused by *Escherichia coli*, 22 Klebsiella pneumoniae, and Enterococcus faecalis, with most encounters treated empirically. As rates of 23 antimicrobial resistance increase, available antibiotic treatment options are dwindling. Novel antibiotics 24 approved for treating bUTIs are limited, leading to a resurgence of interest in older antibiotics, including 25 fosfomycin. In this study, clinical urine samples from patients diagnosed with bUTIs from a military 26 hospital on the Eastern Seaboard of the United States were tested for susceptibility to fosfomycin and 27 comparator antibiotics, including levofloxacin, nitrofurantoin, and trimethoprim-sulfamethoxazole 28 (TMS). A total of 1353 nonduplicate bacterial isolates were tested. The majority were Gram-negative, 29 including 605 non-ESBL and 285 ESBL E. coli and 84 non-ESBL and 52 ESBL K. pneumoniae. Fosfomycin 30 susceptibility rates were similar for non-ESBL and ESBL E. coli (95.9% vs 96.1%) and K. pneumoniae 31 (38.1% vs 36.5%). Fosfomycin demonstrated high activity against other Enterobacterales and Gram-32 positive organisms including Enterobacter faecalis and Staphylococcus aureus. Interestingly, most 33 fosfomycin non-susceptible isolates were susceptible to other first-line bUTI treatment options, and 34 most isolates that were non-susceptible to other first-line bUTI treatment option were susceptible to 35 fosfomycin. ESBL K. pneumoniae isolates were the least susceptible to current first-line treatment 36 options. Fosfomycin Etest demonstrated high sensitivity compared to agar dilution, making it a viable 37 method in resource limited areas. Overall, we demonstrated fosfomycin has high activity against 38 common etiologies that cause bUTIs. Further studies investigating the use of fosfomycin in treating non-E. coli bUTI pathogens, as single or combination therapy, is warranted. 39

40 IMPORTANCE (150 words max)

Uncomplicated bUTI are often caused by *Escherichia coli, Klebsiella pneumoniae*, and *Enterococcus faecalis*, and treated with antibiotics. As rates of antimicrobial resistance increase, the options available

43 for treatment are diminishing. Limited novel antibiotics have entered the market leading to a resurgence 44 of interest in older antibiotics, including fosfomycin. In this study, we investigated the susceptibility of 45 bUTI clinical isolates to fosfomycin and current treatment. Isolates were susceptible to fosfomycin at 46 similar or higher rates compared to comparator antibiotics, especially for isolates that produce 47 extended-spectrum beta-lactamases. In addition to E. coli and E. faecalis, organisms that fosfomycin is 48 FDA approved for, fosfomycin had high activity against other Enterobacterales and Gram-positive 49 organisms including *Staphylococcus aureus*. Since most uncomplicated cystitis is treated empirically, 50 fosfomycin is a reasonable treatment option, either single agent or in combination, supporting the need 51 for randomized control trials to approve treatment of other etiologies, and harmonizing breakpoints 52 across agencies.

53 INTRODUCTION

54 Bacteremic urinary tract infections (bUTIs) are common, and can present as asymptomatic or 55 symptomatic uncomplicated, or complicated infections. This distinction is important since it helps guide 56 the choice and duration of antimicrobial treatment (1). Asymptomatic bacteriuria may not warrant 57 treatment, especially in women, and is now recognized as an important contributor to inappropriate 58 antimicrobial use and the emergence of drug resistance (1,2). The most common causes of bUTIs are 59 infections by Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecalis, complicated by the 60 increasing rate of multidrug resistant (MDR) organisms including the extended-spectrum β -lactamase 61 (ESBL) producing strains of *E. coli* and *K. pneumoniae* (3,4). For uncomplicated acute bacterial cystitis, 62 preferred treatments include nitrofurantoin and trimethoprim/sulfamethoxazole (TMS), and more 63 recently fosfomycin, with fluroquinolones and beta-lactam agents used as alternative treatment options 64 (1).

Fosfomycin is a bactericidal antibiotic agent with a broad spectrum activity against Gram-negative and
Gram-positive pathogens, including MDR Gram-negative pathogens, such as ESBL-producing organisms
and carbapenem-resistant Enterobacterales (CRE) (5,6). Discovered in 1969 (7), the oral formulation
(fosfomycin trometamol) was approved by the United States Food and Drug Administration (FDA) in
1996, and is one of the recommended first-line treatment options for uncomplicated bUTIs caused by *E. coli* or *E. faecalis* (1,2).

71 Due to the limited selection of oral antibiotics to treat bUTIs caused by non-*E. coli* pathogens, especially

those that are resistant, fosfomycin usage is increasing (1,6). In a meta-analysis of randomized

controlled trials (RCTs) assessing the effectiveness and safety for the treatment of cystitis, fosfomycin

trometamol was shown to be as effective with clinical and microbiological cure, relapses, and

75 reinfections as comparator antibiotics including quinolones, β-lactams, aminoglycosides, nitrofurantoin,

and sulfonamides (8). Furthermore, observational studies have demonstrated fosfomycin is effective in

the treatment of MDR infections (9,10), with oral fosfomycin trometamol having similar clinical and

78 microbiological success with carbapenems in the treatment of ESBL-producing E. coli (11). More

recently, the FOREST randomized trial showed that fosfomycin trometamol was an effective oral step-

80 down therapy for bUTIs due to MDR *E. coli* compared to other oral drugs (12). With the rates of MDR

81 pathogens increasing worldwide including in the US, the use of fosfomycin for the treatment of bUTIs is

82 on the rise and is likely to increase, warranting additional studies.

Given that bacterial susceptibility profiles can differ regionally, we sought to get a better understanding
of the *in vitro* activity of fosfomycin and other first-line antibiotics against bUTI pathogens from the mid-

85 Atlantic region of the United States. In this study we determined the efficacy of fosfomycin,

86 nitrofurantoin, levofloxacin, and trimethoprim/sulfamethoxazole (TMS) against clinical bUTI isolates

87 from a military hospital on the US Eastern Seaboard. Furthermore, we sought to examine the efficacy of

88 fosfomycin against MDR isolates as well as species other than *E. coli* and *E. faecalis*.

89 MATERIALS AND METHODS

This study protocol was approved by the appropriate Human subjects regulatory authority. Investigators
adhered to the policies for protection of human subjects as prescribed in 45 Code of Federal Regulation
46.

93 Bacterial isolates

94 A total of 1353 nonduplicate bacterial isolates from urine clinical specimens submitted to the clinical

- 95 laboratory for bUTI testing in our hospital as routine patient standard-of-care were analyzed in this
- 96 study. Single bacterial colonies obtained from purity plates prepared while setting up automated
- 97 identification and susceptibility testing on the BD Phoenix system (Becton Dickinson, New Jersey, US)

98 were used for fosfomycin susceptibility testing, which was performed within 24 hours. Fosfomycin

- 99 susceptibility testing was performed on select isolates at the request of infectious disease clinicians, or
- 100 randomly selected from the urine bench on the days when fosfomycin testing was performed.

101 In vitro susceptibility testing

102 Susceptibilities of all isolates to fosfomycin (Sigma Chemical Co., St. Louis, MO) was determined by the 103 agar dilution method as described by CLSI, with clinical breakpoints for E. coli and E. faecalis from the 104 urinary tract set at is $\leq 64 \ \mu g/ml$ (13,14). For fosfomycin susceptibility testing, plates were prepared using 105 Mueller-Hinton agar (MHA, BBL Microbiology Systems, Cockeysville, MD) supplemented with 25 µg/ml 106 of glucose-6-phosphate and fosfomycin at one of the three concentrations: $64 \mu g/ml$; 128 $\mu g/ml$; 256 107 µg/ml. Bacteria colonies obtained from the purity plates were prepared to 0.5 McFarland and then each 108 isolate spread on four plates; three with fosfomycin (at the three different concentrations) and a control 109 plate that did not contain any antibiotic. Plates were incubated for 16-18 hours at 37°C. The MIC of each 110 antimicrobial agent was defined as the lowest concentration that inhibited visible growth of the 111 organism. Control strains, including S. aureus ATCC 29213, E. coli ATCC 25922, and P. aeruginosa ATCC

- 112 27853, were included in each set of tests. Fosfomycin Etest was performed on MHA agar following
- 113 manufacturer's recommendations (bioMérieux, Durham, NC).

114 Interpretation of susceptibility test results

- 115 Interpretive criteria for susceptibility categories by MIC were applied using the CLSI interpretive criteria
- for urinary tract isolates of *E. coli* and *E. faecalis* for all the isolates as follows: If bacteria grew in the
- 117 control plate and plate containing 64 μg/ml fosfomycin, but not in 128 and 256 μg/ml fosfomycin, it was
- 118 considered susceptible; If bacteria grew in the control plate, and in plates containing 64 μg/ml and 128
- μg/ml fosfomycin but not 256 μg/ml, it was considered intermediate; if bacteria grew in all the plates
- including those containing 256 µg/ml fosfomycin, it was considered resistant. Etest endpoints were read
- 121 by following the manufacturer's package insert, which permits ≤5 colonies within the ellipse to be
- 122 ignored.

123 Data analysis

- 124 MIC data for comparator antibiotics were obtained from the BD Phoenix system and fosfomycin data
- 125 were obtained from agar dilution and Etest. Isolates that were determined to have intermediate

126 susceptibility were considered non-susceptible for analysis. Descriptive statistics were calculated in Excel

127 and Tableau was used for data representation.

128 RESULTS

- 129 Of the 1353 bUTI isolates tested, 89.7% (n=1,213) were Gram-negative and 10.3% (n= 140) were Gram-
- positive. Species with more than 10 bacterial isolates made up 98% (n=1,326) of all organisms tested,
- 131 with *E. coli, K. pneumoniae,* and *E. faecalis* accounting for the majority (84.0%, n=1,137). The remaining
- 132 species that composed our results were *Pseudomonas aeruginosa*, *Citrobacter spp*, *Proteus mirabilis*,

133 Enterococcus faecium, Enterobacter cloacae, Klebsiella aerogenes, Klebsiella oxytoca, and

134 *Staphylococcus aureus* (Figure 1).

135 Antibiotic Susceptibility of Bacterial Isolates

136 Minimum inhibitory concentration (MIC) values for each antibiotic (fosfomycin, levofloxacin, TMS, and

137 nitrofurantoin) were obtained in 1,326 (of the total 1,353) bacterial isolates (supplementary file 1). Most

species exhibited high rates of susceptibility to fosfomycin (92-100%) except for *P. aeruginosa, E.*

- 139 *cloacae,* and *Klebsiella spp* which had fosfomycin susceptibilities of less than 56%.
- 140 Since Citrobacter spp and P. mirabilis had high fosfomycin susceptibility rates (96.2% and 92.3%,
- respectively), and had over 25 isolates, we also evaluated the most common susceptibility patterns in

142 these two species. *Citrobacter spp* overall were more susceptible to the antibiotics tested than P.

- 143 *mirabilis*. While only 50% of isolates were susceptible to amoxicillin, 92.3% were susceptible to
- 144 levofloxacin, 84.6% were susceptible to nitrofurantoin, and 88.5% were susceptible to TMS
- 145 (Supplementary Figure 1). All *Citrobacter spp* isolates were susceptible to at least two antibiotics tested.
- 146 While only 11.5% of *P. mirabilis* isolates were susceptible to nitrofurantoin, 64.5% were susceptible to
- 147 levofloxacin, 73.1% were susceptible to TMS, and 96.2% were susceptible to amoxicillin (Supp Figure 1).
- 148 Like the Citrobacter spp isolates, all P. mirabilis isolates were susceptible to at least two of the

149 antibiotics tested.

150 Antibiotic susceptibility in ESBL vs non-ESBL isolates

Susceptibility profiles for fosfomycin and comparator antibiotics of *E. coli* and *K. pneumoniae* isolates
 identified as ESBL and non-ESBL strains are represented in Figure 2. There were n=605 non-ESBL and
 n=285 ESBL *E. coli*, n= 84 non-ESBL and n=52 ESBL *K. pneumoniae* isolates.

154	Fosfomycin susceptibility rates were similar for non-ESBL and ESBL <i>E. coli</i> (95.9% vs 96.1%) and <i>K.</i>
155	pneumoniae, albeit at much lower rates (38.1% vs 36.5%). For the comparator antibiotics, with
156	exception of nitrofurantoin in E. coli where susceptibility rates were similar for non-ESBL and ESBL
157	(97.5% vs 95.8%), percentage susceptibility rates for <i>E. coli</i> and <i>K. pneumonia</i> were about twice or more
158	(≥83.0%) for non-ESBL compared to ESBL (≤44.0%) isolates. Of note, fosfomycin susceptibility profiles
159	appeared to be similar in all species, except for <i>K. pneumoniae</i> . The susceptibility profiles of non-ESBL <i>K.</i>
160	pneumoniae indicate that levofloxacin and TMS appear to are more effective (Figure 2).
161	Susceptibility of multiple-drug resistant (MDR) <i>E. coli</i> and <i>K. pneumoniae</i> isolates to fosfomycin
162	We then grouped isolates as MDR based on susceptibility to comparator drugs. When we grouped
163	isolates based on non-susceptibility to levofloxacin and TMS, there were 30 (5.0%) non-ESBL and 121
164	(42.5%) ESBL E. coli MDR isolates, of which all but one non-ESBL and seven ESBL were susceptible to
165	fosfomycin (Figure 3A). For ESBL K. pneumoniae, there were 19 (36.5%) MDR isolates, of which 5 (26.3%)
166	were susceptible to fosfomycin. There were only two non-ESBL K. pneumoniae MDR isolates, and one
167	was resistant to fosfomycin (Figure 3B). When we grouped isolates based on non-susceptibility to
168	levofloxacin, TMS and nitrofurantoin, there were 5 non-ESBL (0.8%) and 5 (1.8%) ESBL E. coli MDR
169	isolates, of which all but one non-ESBL and one ESBL were susceptible to fosfomycin (Figure 3A). For
170	ESBL K. pneumoniae, there were 17 (32.7%) MDR isolates, of which 5 (29.4%) were susceptible to
171	fosfomycin. Only one of the non-ESBL K. pneumoniae isolates was resistant to all three comparator
172	drugs but it was susceptible to fosfomycin (Figure 3B). Finally, we grouped ESBL E. coli and K.
173	pneumoniae as MDR based on non-susceptibility to the additional antibiotics tested in the automated
174	AST platform including amoxicillin/clavulanate, aztreonam, cefepime and ceftriaxone. Of the 285 ESBL E.
175	<i>coli</i> isolates, 89 were MDR, of which 83 (93.3%) were fosfomycin susceptible. There were 52 ESBL <i>K</i> .
176	pneumoniae isolates, 27 were MDR, of which 10 (37.0%) were fosfomycin susceptible.

177 Susceptibility of fosfomycin-resistant isolates to comparator drugs

- 178 Of the 25 *E. coli* non-ESBL isolates that were fosfomycin resistant, 23 (92.0%) were susceptible to
- 179 nitrofurantoin and TMS, and of the 15 isolates that were nitrofurantoin resistant, 13 (86.7%) were
- 180 susceptible to fosfomycin (Figure 3A). Of the 11 *E. coli* ESBL isolates that were fosfomycin resistant, 10
- 181 (90.9%) were susceptible to nitrofurantoin, 3 (27.3%) were susceptible to TMS, and only one (9.1%) was
- 182 susceptible to levofloxacin. Of the 12 nitrofurantoin-resistant ESBL isolates, 11 (91.7%) were susceptible
- to fosfomycin, and 6 (50.0%) were susceptible to TMS. Of the 52 fosfomycin resistant non-ESBL K.
- 184 pneumoniae isolates, 20 (38.4%) were susceptible to nitrofurantoin, levofloxacin, and TMS, and 43
- 185 (82.7%) were susceptible to levofloxacin and TMS. Fosfomycin resistant ESBL K. pneumoniae isolates did
- 186 not display a predominant susceptibility pattern to comparator drugs (Figure 3B).

187 Global susceptibility profiles of E. coli, K. pneumoniae and E. faecalis

- 188 The global susceptibilities of the isolates to the four antibiotics tested in this study were examined.
- 189 Isolates were grouped based on the number of antibiotics they were susceptible to. ESBL K. pneumoniae
- displayed the lowest susceptibilities, with 23% of isolates pan-resistant to the four antibiotics tested.
- 191 Conversely, non-ESBL *E. coli* exhibited the highest susceptibilities, with 71% of isolates pan-susceptible
- to all antibiotics, and only one was pan-resistant to all the antibiotics tested. The other three groups of
- isolates displayed at least 50% susceptibility to at least three antibiotics tested (Figure 4).

194 Common susceptibility patterns in E. coli, K. pneumoniae and E. faecalis

- 195 To understand the most common susceptibility patterns, isolates for each species were grouped by
- identical antibiotic susceptibilities (Figure 5). The most common susceptibility pattern for non-ESBL E.
- 197 *coli* isolates was susceptible to fosfomycin, levofloxacin, TMS, and nitrofurantoin, which was present in
- 198 430 (71.1%) of the isolates. The most common pattern in ESBL *E. coli* was susceptible to fosfomycin and
- nitrofurantoin but non-susceptible to levofloxacin and TMS, detected in 110 (38.6%) of the isolates.

While three susceptibility patterns were prominent in non-ESBL *K. pneumoniae*, the most common
pattern, with 23 (27.4%) isolates, was susceptible to levofloxacin and TMS but non-susceptible to
fosfomycin and nitrofurantoin. Interestingly, the susceptibility pattern that was most common in ESBL *K. pneumoniae* was non-susceptible to all four antibiotics tested. ESBL *K. pneumoniae* exhibited the
highest number of susceptibility patterns, 14 out of the possible 16 patterns represented (Figure 3). The
majority of *E. faecalis* isolates (66 [71.0%]) were susceptible to fosfomycin, levofloxacin, and
nitrofurantoin but non-susceptible to TMS.

207 Comparison of agar dilution and Etest outcomes

208 Given that agar dilution (AD) is time and material-intensive, we tested if the Etest, which may be more

209 practical for many labs performing surveillance, especially in resource-limited areas, could provide

210 accurate results. Fosfomycin susceptibility profiles were established using the Etest in the following

211 bacterial isolates: 477 E. coli, of which 34 were ESBLs; 96 K. pneumoniae, of which 11 were ESBLs; and 45

212 E. faecalis. There was a dramatic range in MICs (Figure 6), which led to more considerable than expected

213 disparities between the median and average MICs (Table 1). Overall *E. coli* was highly susceptible

compared to *K. pneumoniae* for non-ESBLs (99.8% vs. 50.6%) and ESBLs (91.0% vs. 45.5%) and *E. faecalis*

had high susceptibility rates (88.9%) (Table 1). Of the 116 isolates tested for fosfomycin susceptibility by

both Etest and AD, 116 (100.0%) were identified as susceptible by AD but only 109 (94.0%) were

- identified as susceptible by Etest. Three misidentified isolates had MICs greater than 256 μg/mL.
- 218 Table 1. Isolate susceptibility to fosfomycin determined by the Etest

		Non-ESBL			
	E. coli	K. pneumoniae	E. coli K. pneumoniae		E. faecalis
Median	1	96	1.5	64	32

Average	15.2	255.8	8.22	81.8	40.2
Standard	109.3	372.5	24.1	57.3	28.0
Deviation					
Percent	99.8	50.6	91.0	45.5	88.9
susceptible					
Percent	95.9	36.4	96.4	37.3	98.0
susceptible (AD)					

219

220 DISCUSSION

221 In this study, we evaluated fosfomycin activity against common bUTI organisms collected from a military 222 hospital located in the Eastern Seaboard of the United States using CLSI breakpoints for E. coli and E. 223 faecalis. In addition to showing high activity against these two organisms, fosfomycin also displayed high 224 activity against other common bUTI organisms, including Enterobacterales (Citrobacter spp and P. 225 mirabilis) and Gram-positive organisms (S. aureus and E. faecium). Further, fosfomycin displayed high 226 activity against ESBL and MDR E. coli isolates, with similar susceptibility rates as those for non-ESBL 227 isolates. Nitrofurantoin displayed similarly high activity against *E. coli* as fosfomycin. Interestingly, most 228 fosfomycin non-susceptible isolates were susceptible to nitrofurantoin, and most nitrofurantoin non-229 susceptible isolates were susceptible to fosfomycin. Fosfomycin displayed least activity against K. 230 pneumoniae, both non-ESBL and ESBL isolates. Fosfomycin non-susceptible non-ESBL K. pneumoniae 231 were highly susceptible to levofloxacin and TMS but not nitrofurantoin. Fosfomycin also displayed low 232 activity against K. aerogenes, E. cloacae and P. aeruginosa. The susceptibility rates in our study 233 corroborated a recent study which showed *P. aeruginosa* with susceptibility rate of 40.4% to fosfomycin 234 (15). 235 As a primary or step-down bUTI treatment, fosfomycin has been shown to have high clinical,

236 microbiological, and *in vitro* activity against MDR *E. coli*, including those harboring metallo-β-lactamases

237 (12, 16-26). Oral fosfomycin tromethamine is FDA-approved for single-dose treatment of uncomplicated

238 bUTI (23,27). As the predominant bUTI pathogen, most published studies investigating clinical, 239 microbiological, and *in vitro* activity of fosfomycin have primarily focused on *E. coli* (28). There are 240 however studies that have also investigated activity of fosfomycin against other common bUTI species. A 241 study by Mezzatesta et al., found in addition to having high activity against ESBL E. coli, fosfomycin had 242 high in vitro activity against ESBL P. mirabilis and methicillin-resistant S. saprophyticus (5). Other studies 243 have also demonstrated high fosfomycin in vitro activity against Enterobacterales, including Proteus spp, 244 Enterobacter spp, Serratia spp, and Citrobacter spp (28,29). These studies corroborate part of our data 245 where we demonstrated high fosfomycin in vitro activity against P. mirabilis and Citrobacter spp but not 246 Enterobacter. Further, similarly to our study, studies have demonstrated that fosfomycin retains high in 247 vitro activity against bacterial isolates that are non-susceptible to other first-line treatments for bUTI 248 (28,29).

249 Fosfomycin in vitro activity against K. pneumoniae seems to vary widely between studies but remains 250 consistently lower than that of most other Enterobacterales (5, 27-30). Interestingly, high clinical and 251 microbiological cures have been attained in patients treated with fosfomycin due to bUTI caused by K. 252 pneumoniae (31-33). Although the epidemiology and susceptibility of different organisms may vary 253 based on the country and region, these data strongly suggest fosfomycin is a highly active antibiotic 254 against the most common causes of bUTI and has a high clinical cure rate. This is important since most 255 uncomplicated bUTI are treated empirically (34). Therefore, an antibiotic that provides broad-spectrum 256 activity, including activity against MDR organisms with good clinical outcomes, is a reasonable treatment option. Further, fosfomycin is a highly viable option as a step-down treatment (12,18,20). RCTs will be 257 258 invaluable in investigating fosfomycin effectiveness in treating other common bUTI pathogens including 259 *K. pneumoniae*, especially in regions with high rates of MDR organisms.

Fosfomycin tromethamine is an antibacterial phosphonic acid that inhibits bacterial cell wall formation
by interfering with peptidoglycan synthesis (35). *In vitro* synergy between fosfomycin and other

262 antibiotics has been demonstrated, which may be useful as an alternative treatment option, especially 263 for MDR organisms including K. pneumoniae, P. aeruginosa, Acinetobacter baumannii and methicillin-264 resistant S. aureus (36). The synergistic effect between fosfomycin and β-lactam antibiotics is proposed 265 to arise from the inhibition of cell wall synthesis at separate steps, and ciprofloxacin is due to 266 ciprofloxacin-mediated damage to the outer membrane, which increases the penetration and activity of 267 fosfomycin (35,37-38). In *P. aeruginosa, in vitro* studies demonstrated synergy between fosfomycin and 268 a variety of other antibiotics, including aztreonam, cefepime, meropenem, imipenem, ceftazidime, 269 gentamycin, amikacin, ciprofloxacin, and others (37-40). Further, the synergistic activity of fosfomycin, 270 ciprofloxacin, and gentamicin against E. coli and P. aeruginosa biofilms has been demonstrated (41), 271 making it a reasonable treatment option for patients with catheters. RCTs investigating fosfomycin as a 272 combination therapy have shown higher clinical and microbiological success rates in many different 273 infections, including sepsis/bacteremia and respiratory tract infections (25, 42,43). However, to the best 274 of our knowledge, RCTs investigating fosfomycin as a combination therapy in treating UTIs have not 275 been conducted (42). In our study, with the exception of one isolate, all fosfomycin-resistant E. coli were 276 susceptible to either all or at least one of the comparator UTIs first-line or alternate drugs. Clinical 277 studies have compared the efficacy of fosfomycin to comparator UTI first-line drugs and have shown it 278 to be a valuable alternative option (24, 42, 44-47). In a study investigating treatment patterns and 279 clinical outcomes among females with uncomplicated bUTI in Germany that were empirically treated, 280 the incidence of recurrent infection in the 6-month post-index period was higher in patients with E. coli 281 that were resistant to one of the first-line treatments (48). With antimicrobial susceptibility rates and 282 epidemiology of bUTI pathogens different and rapidly changing from one region to another, robust 283 research with well-designed double-blinded RCTs investigating the use of fosfomycin as a combination 284 therapy for the treatment of bUTIs, especially in patients with recurrent infections, is warranted.

285 Similar to the European Committee on Antimicrobial Susceptibility Testing (EUCAST), the Clinical and 286 Laboratory Standards Institute (CLSI) recognizes AD as the reference method for fosfomycin 287 susceptibility testing for E. coli and E. faecalis (13,49,50). AD is a labor- and time-intensive methodology, 288 which has led to many laboratories using either disk diffusion, which is only approved for E. coli from 289 urine samples by CLSI (50), or Etest, which is only approved by EUCAST (49) but not CLSI. This is further 290 complicated by differences in breakpoints between CLSI and EUCAST, which also varies by specimen 291 types (51). Etests, based on a combination of dilution and diffusion testing, offer valuable solutions since 292 they provide MICs. However, there are concerns about the accuracy of Etest results, which can also be 293 challenging to interpret due to micro- and macro-colonies (51, 52). A recent new formulation of the 294 fosfomycin Etest showed high accuracy, which is vital as an alternative to AD (49-51). In our study, using 295 AD as a reference method, data produced using Etest had sensitivity closer to 95%, making it a viable 296 method for fosfomycin testing in addition to disk diffusion. Etests provide MIC values, which may be 297 helpful in clinical decisions if the recently developed novel Etest formulations perform consistently in 298 other laboratories' hands (51). In that case, CLSI should support studies validating the use of Etest as a 299 susceptibility testing option for fosfomycin, given the numerous challenges of using AD in susceptibility 300 testing and the limitations of disk diffusion.

301 In conclusion, *in vitro* data from our patient population demonstrate that in addition to *E. coli*,

302 fosfomycin has high activity against several of the most common Gram-negative and Gram-positive bUTI

303 pathogens, including those that are MDR. Furthermore, we've shown that the Etest is a viable

alternative for fosfomycin susceptibility testing. However, RCTs investigating fosfomycin for the

305 treatment of bUTIs due to organisms other than *E. coli* are lacking whereas clinical, microbiologic, and in

306 *vitro* data strongly suggest this is a viable treatment option. Since bUTIs are among the most common

307 bacterial infections worldwide, occurring in both community and in healthcare settings, and most are

308 usually treated empirically (34), having an effective treatment option against MDR pathogens will play

- 309 an essential role in managing bUTIs worldwide and antimicrobial stewardship programs. RCTs
- 310 investigating the use of fosfomycin in treating non-*E. coli* bUTI pathogens and as a combination therapy
- for treating UTIs, especially in patients with recurrent infections, are long overdue.
- 312

313 ACKNOWLEDGMENTS

- 314 Disclaimer: The views expressed in this manuscript are those of the authors and do not necessarily
- reflect the official policy of the Department of Defense, Department of Army, US Army Medical
- 316 Department, Defense Health Agency, or the US Government. The study protocol was approved by the
- 317 appropriate Human subjects regulatory authority. Investigators adhered to the policies for protection of
- human subjects as prescribed in 45 Code of Federal Regulation 46.
- 319 Conflicts of interest: The authors declare no conflicts of interest.
- 320 Ethical statement: The institution's ethical review board and the human research protection office at the
- 321 Defense Health Agency and Tripler Army Medical Center reviewed and approved this study.
- 322

- 324
- 325
- 326
- 327
- 328
- 329

330 **REFERENCES**

222		Constitute CE, Chained Branchattana and E, identifications of functions. The state fractions (Misselfield
332	1.	Geerlings SE. Clinical Presentations and Epidemiology of Urinary Tract Infections. Microbiol
333	2	Spectr. 2016 Oct;4(5). doi: 10.1128/microbiolspec.UTI-0002-2012. PMID: 27780014.
334	Ζ.	Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, Eckert LO, Geerlings SE, Köves
335		B, Hooton TM, Juthani-Mehta M, Knight SL, Saint S, Schaeffer AJ, Trautner B, Wullt B, Siemieniuk
336		R. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by
337		the Infectious Diseases Society of America. Clin Infect Dis. 2019 May 2;68(10):e83-e110. Doi:
338	-	10.1093/cid/ciy1121. PMID: 30895288.
339	3.	Keepers TR, Gomez M, Celeri C, Krause KM, Biek D, Critchley I. Fosfomycin and Comparator
340		Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract
341		Infection Isolates from the United States in 2012. Infect Dis Ther. 2017 Jun;6(2):233-243. doi:
342		10.1007/s40121-017-0150-5. Epub 2017 Mar 11. PMID: 28285420; PMCID: PMC5446363.
343	4.	Mosime LB, Newton-Foot M, Nel P. Fosfomycin resistance in community-acquired urinary
344		pathogens from Western Cape, South Africa. S Afr J Infect Dis. 2022 Jan 19;37(1):321. doi:
345		10.4102/sajid.v37i1.321. PMID: 35169586; PMCID: PMC8831924.
346	5.	Mezzatesta ML, La Rosa G, Maugeri G, Zingali T, Caio C, Novelli A, Stefani S. In vitro activity of
347		fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens. Int J
348		Antimicrob Agents. 2017 Jun;49(6):763-766. doi: 10.1016/j.ijantimicag.2017.01.020. Epub 2017
349		Apr 5. PMID: 28390962.
350	6.	Vardakas KZ, Legakis NJ, Triarides N, Falagas ME. Susceptibility of contemporary isolates to
351		fosfomycin: a systematic review of the literature. Int J Antimicrob Agents. 2016 Apr;47(4):269-85.
352		doi: 10.1016/j.ijantimicag.2016.02.001. Epub 2016 Feb 24. PMID: 27013000.
353	7.	Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK, Wolf FJ, Miller TW, Chaiet L, Kahan FM,
354		Foltz EL, Woodruff HB, Mata JM, Hernandez S, Mochales S. 1969. Phosphonomycin, a new
355		antibiotic produced by strains of streptomyces. Science 166:122–123. doi:
356		10.1126/science.166.3901.122.
357	8.	Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016
358		Apr;29(2):321-47. doi: 10.1128/CMR.00068-15. PMID: 26960938; PMCID: PMC4786888.
359	9.	Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the
360		treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related lower
361		urinary tract infections. Int J Antimicrob Agents. 2007 Jan;29(1):62-5. doi:
362		10.1016/j.ijantimicag.2006.08.039. PMID: 17189097.
363	10.	Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, Tórtola T, Mirelis B,
364		Navarro G, Cuenca M, Esteve M, Peña C, Llanos AC, Cantón R, Pascual A. Community infections
365		caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008
366		Sep 22;168(17):1897-902. doi: 10.1001/archinte.168.17.1897. PMID: 18809817.
367	11.	Senol S, Tasbakan M, Pullukcu H, Sipahi OR, Sipahi H, Yamazhan T, Arda B, Ulusoy S. Carbapenem
368		versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-
369		producing Escherichia coli-related complicated lower urinary tract infection. J Chemother. 2010
370		Oct;22(5):355-7. doi: 10.1179/joc.2010.22.5.355. PMID: 21123160.
371	12.	Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, Morales IM, Palacios-Baena ZR,
372		Hernández-Torres A, Merino de Lucas E, Escolà-Vergé L, Bereciartua E, García-Vázquez E, Pintado
373		V, Boix-Palop L, Natera-Kindelán C, Sorlí L, Borrell N, Giner-Oncina L, Amador-Prous C, Shaw E,
374		Jover-Saenz A, Molina J, Martínez-Alvarez RM, Dueñas CJ, Calvo-Montes J, Silva JT, Cárdenes MA,
375		Lecuona M, Pomar V, Valiente de Santis L, Yagüe-Guirao G, Lobo-Acosta MA, Merino-Bohórquez
376		V, Pascual A, Rodríguez-Baño J; REIPI-GEIRAS-FOREST group. Effectiveness of Fosfomycin for the
575		, accurry noungaez band y nen i denno i dneor group, encentencos di rosioniyen for the

377		Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A
378		Randomized Clinical Trial. JAMA Netw Open. 2022 Jan 4;5(1):e2137277. doi:
379		10.1001/jamanetworkopen.2021.37277. PMID: 35024838; PMCID: PMC8759008
380	13.	Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial
381		susceptibility testing; twenty-third informational supplement. M100-S23. Clinical and Laboratory
382		Standards Institute, Wayne, PA.
383	14.	Clinical and Laboratory Standards Institute 2009. Methods for dilution susceptibility tests for
384		bacteria that grow aerobically; approved standard. M7-A8, 8th ed Clinical and Laboratory
385		Standards Institute, Wayne, PA
386	15.	Smith EC, Brigman HV, Anderson JC, Emery CL, Bias TE, Bergen PJ, Landersdorfer CB, Hirsch EB.
387		Performance of Four Fosfomycin Susceptibility Testing Methods against an International
388		Collection of Clinical Pseudomonas aeruginosa Isolates. J Clin Microbiol. 2020 Sep
389		22;58(10):e01121-20. doi: 10.1128/JCM.01121-20. PMID: 32669380; PMCID: PMC7512173.
390	16.	Sojo-Dorado J, López-Hernández I, Hernández-Torres A, Retamar-Gentil P, Merino de Lucas E,
391		Escolà-Vergé L, Bereciartua E, García-Vázquez E, Pintado V, Boix-Palop L, Natera-Kindelán C, Sorlí
392		L, Borrell N, Amador-Prous C, Shaw E, Jover-Saenz A, Molina J, Martínez-Álvarez RM, Dueñas CJ,
393		Calvo-Montes J, Lecuona M, Pomar V, Borreguero I, Palomo-Jiménez V, Docobo-Pérez F, Pascual
394		Á, Rodríguez-Baño J; CIBERINFEC-GEIRAS-FOREST group. Effectiveness of fosfomycin trometamol
395		as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a
396		post hoc analysis of the FOREST randomized trial. J Antimicrob Chemother. 2023 Jun 1:dkad147.
397		doi: 10.1093/jac/dkad147. Epub ahead of print. PMID: 37260299.
398	17.	Bakthavatchalam YD, Shankar A, Manokaran Y, Walia K, Veeraraghavan B. Can fosfomycin be an
399		alternative therapy for infections caused by E. coli harbouring dual resistance: NDM and four-
400		amino acid insertion in PBP3? JAC Antimicrob Resist. 2023 Mar 4;5(2):dlad016. doi:
401		10.1093/jacamr/dlad016. PMID: 36880086; PMCID: PMC9985326.
402	18.	Burgos J, Hoyos-Mallecot Y, Ferre-Losa C, Arando M, Monforte A, Pumarola T, Los-Arcos I, Falcó V.
403		Oral fosfomycin for treatment of acute bacterial prostatitis caused by multidrug-resistant
404		Enterobacterales. Microbiol Spectr. 2023 Sep 22;11(5):e0213623. doi: 10.1128/spectrum.02136-
405		23. Epub ahead of print. PMID: 37737627; PMCID: PMC10580941.
406	19.	Vahiddastjerdi M, Vaghar ME, Dashtaki SG. Evaluation of Efficacy of Fosfomycin for the
407	-	Treatment of Patients with Lower Urinary Tract Infections (UTIs). Maedica (Bucur). 2023
408		Dec;18(4):593-597. doi: 10.26574/maedica.2023.18.4.593. PMID: 38348083; PMCID:
409		PMC10859210.
410	20	Ten Doesschate T, Kuiper S, van NieuwkoopC. 2021. FORECAST study team. Fosfomycin versus
411	20.	ciprofloxacin as oral stepdown treatment for Escherichia coli febrile urinary tract infection in
412		women: a randomized, placebo-controlled, double blind, multicenter trial. Clin Infect
413		Dis:ciab934.
414	21	Falagas M.E., Kanellopoulou M.D., Karageorgopoulos D.E., Dimopoulos G., Rafailidis P.I.,
415	21.	Skarmoutsou N.D., Papafrangas E.A. Antimicrobial susceptibility of multidrug-resistant Gram
416		negative bacteria to fosfomycin. Eur. J. Clin. Microbiol. Infect. Dis. 2008;27:439–443. doi:
410		10.1007/s10096-007-0456-4. [PubMed] [CrossRef] [Google Scholar]
417 418	วว	Falagas ME, Vouloumanou EK, Togias AG, Karadima M, Kapaskelis AM, Rafailidis PI, Athanasiou S.
	۲۲.	
419		Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized
420		controlled trials. J Antimicrob Chemother. 2010 Sep;65(9):1862-77. doi: 10.1093/jac/dkq237.
421		Epub 2010 Jun 29. PMID: 20587612.

422	23. Falagas M.E., Maraki S., Karageorgopoulos D.E., Kastoris A.C., Mavromanolakis E., San	
423	Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resista	
424	Enterobacteriaceae isolates to fosfomycin. Int. J. Antimicrob. Agents. 2010;35:240–24	13. doi:
425	10.1016/j.ijantimicag.2009.10.019. [PubMed] [CrossRef] [Google Scholar]	
426	24. Falagas M.E., Kastoris A.C., Kapaskelis A.M., Karageorgopoulos D.E. Fosfomycin for the	e treatment
427	of multidrug-resistant, including extended-spectrum b-lactamase producing, Enterob	acteriaceae
428	infections: A systematic review. Lancet Infect. Dis. 2010;10:43–50. doi: 10.1016/S147	3-
429	3099(09)70325-1. [PubMed] [CrossRef] [Google Scholar]	
430	25. Michalopoulos A., Virtzili S., Rafailidis P., Halevelakis G.H., Damala M., Falagas M. Intra	avenous
431	fosfomycin for the treatment of nosocomial infections caused by carbapenem-resista	nt Klebsiella
432	pneumoniae in critically ill patients: A prospective evaluation. Clin. Microbiol. Infect.	
433	2010;16:184–186. doi: 10.1111/j.1469-0691.2009.02921.x. [PubMed] [CrossRef] [God	ogle
434	Scholar]	
435	26. Dinh A., Salomon J., Bru J.P., Bernard L. Fosfomycin: Efficacy against infections caused	by
436	multidrug-resistant bacteria. Scand. J. Infect. Dis. 2012;44:182–189. doi:	
437	10.3109/00365548.2011.616221.	
438	27. Lu CL, Liu CY, Huang YT, Liao CH, Teng LJ, Turnidge JD, Hsueh PR. Antimicrobial suscep	tibilities of
439	commonly encountered bacterial isolates to fosfomycin determined by agar dilution a	and disk
440	diffusion methods. Antimicrob Agents Chemother. 2011 Sep;55(9):4295-301. doi:	
441	10.1128/AAC.00349-11. Epub 2011 Jun 13. PMID: 21670185; PMCID: PMC3165352	
442	28. Demir T, Buyukguclu T. Evaluation of the in vitro activity of fosfomycin tromethamine	against
443	Gram-negative bacterial strains recovered from community- and hospital-acquired ur	inary tract
444	infections in Turkey. Int J Infect Dis. 2013 Nov;17(11):e966-70. doi: 10.1016/j.ijid.2013	3.04.005.
445	Epub 2013 Jun 3. PMID: 23742831	
446	29. Fajfr M, Louda M, Paterová P, Ryšková L, Pacovský J, Košina J, Žemličková H, Broďák M	l. The
447	susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infe	ction in the
448	Czech Republic: data from a unicentric study. BMC Urol. 2017 Apr 26;17(1):33. doi:	
449	10.1186/s12894-017-0222-6. PMID: 28446177; PMCID: PMC5406914	
450	30. Linsenmeyer K, Strymish J, Weir S, Berg G, Brecher S, Gupta K. Activity of Fosfomycin	against
451	Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Commu	nity and
452	Hospitalized Patients. Antimicrob Agents Chemother. 2015 Nov 23;60(2):1134-6. doi:	
453	10.1128/AAC.02614-15. PMID: 26596940; PMCID: PMC4750673	
454	31. Vahiddastjerdi M, Vaghar ME, Dashtaki SG. Evaluation of Efficacy of Fosfomycin for th	e
455	Treatment of Patients with Lower Urinary Tract Infections (UTIs). Maedica (Bucur). 20	23
456	Dec;18(4):593-597. doi: 10.26574/maedica.2023.18.4.593. PMID: 38348083; PMCID:	
457	PMC10859210.	
458	32. Minassian MA, Lewis DA, Chattopadhyay D, Bovill B, Duckworth GJ, Williams JD. A cor	nparison
459	between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimeth	
460	the treatment of uncomplicated lower urinary tract infection in women. Int J Antimic	•
461	1998 Apr;10(1):39-47. doi: 10.1016/s0924-8579(98)00021-1. PMID: 9624542.	-
462	33. Karimi A, Afrakhteh M, Aghazadeh Naeini A, Amiri Z. A Comparison of Cephalexin wit	h
463	Fosfomycin Trometanol (monurol) in the treatment of pregnant women with lower u	
464	Yafteh. 2012;13:17–22.	

465	34. Mancuso G, Midiri A, Gerace E, Marra M, Zummo S, Biondo C. Urinary Tract Infections: The
466	Current Scenario and Future Prospects. Pathogens. 2023 Apr 20;12(4):623. doi:
467	10.3390/pathogens12040623. PMID: 37111509; PMCID: PMC10145414.
468	35. Dijkmans AC, Zacarías NVO, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C, Touw DJ,
469	Stevens J, Kamerling IMC. Fosfomycin: Pharmacological, Clinical and Future Perspectives.
470	Antibiotics (Basel). 2017 Oct 31;6(4):24. doi: 10.3390/antibiotics6040024. PMID: 29088073;
471	PMCID: PMC5745467.
472	36. Kastoris AC, Rafailidis PI, Vouloumanou EK, Gkegkes ID, Falagas ME. Synergy of fosfomycin with
473	other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol. 2010
474	Apr;66(4):359-68. doi: 10.1007/s00228-010-0794-5. Epub 2010 Feb 26. PMID: 20186407.
475	37. Samonis G., Maraki S., Karageorgopoulos D.E., Vouloumanou E.K., Falagas M.E. Synergy of
476	fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant
477	Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur. J.
478	Clin. Microbiol. Infect. Dis. 2012;31:695–701. doi: 10.1007/s10096-011-1360-5.
479	38. Yamada S., Hyo Y., Ohmori S., Ohuchi M. Role of ciprofloxacin in its synergistic effect with
480	fosfomycin on drug-resistant strains of Pseudomonas aeruginosa. Chemotherapy. 2007;53:202–
481	209. doi: 10.1159/000100811.
482	39. Okazaki M., Suzuki K., Asano N., Araki K., Shukuya N., Egami T., Higurashi Y., Morita K., Uchimura
483	H., Watanabe T. Effectiveness of fosfomycin combined with other antimicrobial agents against
484	multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J.
484	Infect. Chemother. 2002;8:37–42. doi: 10.1007/s101560200004.
485	40. Tessier F., Quentin C. In vitro activity of fosfomycin combined with ceftazidime, imipenem,
480 487	amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Eur. J. Clin. Microbiol. Infect. Dis.
487	1997;16:159–162. doi: 10.1007/BF01709477
488 489	
	41. Wang L, Di Luca M, Tkhilaishvili T, Trampuz A, Gonzalez Moreno M. Synergistic Activity of
490 491	Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa
	Biofilms. Front Microbiol. 2019 Nov 6;10:2522. doi: 10.3389/fmicb.2019.02522. PMID:
492	31781056; PMCID: PMC6853019.
493	42. Grabein B, Graninger W, Rodríguez Baño J, Dinh A, Liesenfeld DB. Intravenous fosfomycin-back to
494	the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect.
495	2017 Jun;23(6):363-372. doi: 10.1016/j.cmi.2016.12.005. Epub 2016 Dec 9. PMID: 27956267.
496	43. Shaw E, Miró JM, Puig-Asensio M, Pigrau C, Barcenilla F, Murillas J, Garcia-Pardo G, Espejo E,
497	Padilla B, Garcia-Reyne A, Pasquau J, Rodriguez-Baño J, López-Contreras J, Montero M, de la
498	Calle C, Pintado V, Calbo E, Gasch O, Montejo M, Salavert M, Garcia-Pais MJ, Carratalà J, Pujol M;
499	Spanish Network for Research in Infectious Diseases (REIPI RD12/0015); Instituto de Salud Carlos
500	III, Madrid, Spain; GEIH (Hospital Infection Study Group). Daptomycin plus fosfomycin versus
501	daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III
502	trial. BMJ Open. 2015 Mar 11;5(3):e006723. doi: 10.1136/bmjopen-2014-006723. PMID:
503	25762232; PMCID: PMC4360784.
504	44. Hassan MM, Malik M, Saleem R, Saleem A, Zohaib K, Malik AY, Javaid M. Efficacy of Single Dose
505	of Fosfomycin Versus a Five-Day Course of Ciprofloxacin in Patients With Uncomplicated Urinary
506	Tract Infection. Cureus. 2022 May 9;14(5):e24843. doi: 10.7759/cureus.24843. PMID: 35702450;
507	PMCID: PMC9177222

45. Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, Martinez de Tejada B, Roux X, Shiber S, Theuretzbacher U, von Dach E, Yahav D, Leibovici L, Godycki-Cwirko M, Mouton JW, Harbarth S. Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. JAMA. 2018 May 1;319(17):1781-1789. doi: 10.1001/jama.2018.3627. PMID: 29710295; PMCID: PMC6134435.

- 46. Grant R, Büchler A, Flight W, Huang C, Ferrinho D, Janmohamed S, Mulgirigama A, GodyckiCwirko M, Leibovici L, Huttner A, Harbarth S. Impact of the 2019 Food and Drug Administration
 Guidance for Uncomplicated Urinary Tract Infection on Treatment Response Rates: A Reanalysis
 of a Clinical Trial of Nitrofurantoin vs Fosfomycin. Open Forum Infect Dis. 2023 Nov
 4;10(11):ofad557. doi: 10.1093/ofid/ofad557. PMID: 38023546; PMCID: PMC10661658.
- 47. Porreca A, D'Agostino D, Romagnoli D, Del Giudice F, Maggi M, Palmer K, Falabella R, De
 Berardinis E, Sciarra A, Ferro M, Artibani W, Mirone V, Busetto GM. The Clinical Efficacy of
 Nitrofurantoin for Treating Uncomplicated Urinary Tract Infection in Adults: A Systematic Review
 of Randomized Control Trials. Urol Int. 2021;105(7-8):531-540. doi: 10.1159/000512582. Epub
 2021 Feb 3. PMID: 33535221.
- 48. Naber KG, Wagenlehner F, Kresken M, Cheng WY, Catillon M, Duh MS, Yu L, Khanal A,
 Mulgirigama A, Joshi AV, Ju S, Mitrani-Gold FS. Escherichia coli resistance, treatment patterns
 and clinical outcomes among females with uUTI in Germany: a retrospective physician-based
 chart review study. Sci Rep. 2023 Jul 26;13(1):12077. doi: 10.1038/s41598-023-38919-8. PMID:
 37495602; PMCID: PMC10372039.
 - 49. European Committee on Antimicrobial Susceptibility Testing. 2022. Breakpoint tables for interpretation of MICs and zone diameters; version 12.0. <u>http://www.eucast.org</u>
- 50. Clinical and Laboratory Standards Institute. 2022. Performance standards for antimicrobial
 susceptibility testing; thirty-second informational supplement. M100-S32. Clinical and
 Laboratory Standards Institute, Wayne, PA.
- 51. Goer A, Blanchard LS, Van Belkum A, Loftus KJ, Armstrong TP, Gatermann SG, Shortridge D, Olson
 BJ, Meece JK, Fritsche TR, Pompilio M, Halimi D, Franceschi C. Multicenter Evaluation of the
 Novel ETEST Fosfomycin for Antimicrobial Susceptibility Testing of Enterobacterales,
 Enterococcus faecalis, and Staphylococcus Species. J Clin Microbiol. 2022 Jul 20;60(7):e0002122.
 doi: 10.1128/jcm.00021-22. Epub 2022 Jun 23. PMID: 35736011; PMCID: PMC9297813.
- 539 52. van Mens SP, Ten Doesschate T, Kluytmans-van den Bergh MFQ, Mouton JW, Rossen JWA,
- 540 Verhulst C, Bonten MJM, Kluytmans JAJW. Fosfomycin Etest for Enterobacteriaceae:
- 541 Interobserver and interlaboratory agreement. Int J Antimicrob Agents. 2018 Nov;52(5):678-681.
- 542 doi: 10.1016/j.ijantimicag.2018.06.014. Epub 2018 Jun 27. PMID: 29958976.
- 543

529


- 544
- 545
- 546

547 FIGURES

E. coli, 9	03, 95.9%	K. pneumonia 139, 36.7%	₽,	E. 1 95,	faeca 97.9	līs, %
		<i>P. aeruginosa,</i> 47, 55.3%	<i>Citroba</i> 26, 96.3	cter, 2%	E. fa 24, 1	ecium, 00%
		P. mirabilis, 26, 92.3%	EC, 21, 42.9%	KA, 19, 52.69 SA, 1	%	KO, 13, 38.5% 0.0%

548

- 549 **Figure 1.** Susceptibility of bacteria isolates from urinary tract infections to fosfomycin. Bacterial isolates
- 550 (n=1,326) were tested for susceptibility to fosfomycin. E. coli, K. pneumoniae and E. faecalis represented
- the majority of isolates. Species with more than 10 isolates are displayed (note, different *Citrobacter*
- species are combined); data shows species, number of isolates tested, and percent susceptible to
- 553 fosfomycin. EC Enterobacter cloacae; KA Klebsiella aerogenes; SA Staphylococcus aureus; KO Klebsiella
- 554 oxytoca.



556

557 Figure 2. Clinical isolates of *E. coli* and non-ESBL *K. pneumoniae* are susceptible to fosfomycin at

558 similar, or higher rates, than comparator antibiotics. The agar dilution method was used to test

559 whether clinical isolates were susceptible to fosfomycin. Comparator antibiotic susceptibilities were

tested using broth dilution. UTI isolates of E. coli (n-=890), K. pneumoniae (n= 136), and E. faecalis

561 (n=93) were tested for susceptibilities to fosfomycin and comparator antibiotics. Isolates of *E. coli* and *K*.

562 *pneumoniae* were separated by ESBL and non-ESBL to observe antibiotic susceptibilities.

563

564

A	Fos Susceptibility						
	Nitro	Levo	TMS	f	os	RF	OS
	susceptibility	Susceptiblity	susceptibility	E. coli	ESBL E. coli	E. coli	ESBL E. coli
		lev	tms	430	54	18	
	nitro	iev	RTMS	68	35		1
		RLEV	tms	44	64	5	3
			RTMS	25	110		6
	lov	lev	tms	5	1	1	
	RNITRO	lev	RTMS	3	1		
	NULKO	RLEV	tms	1	5		
		IXLL V	RTMS	4	4	1	1

В

			Fos Susceptibility			
			f	os	RF	OS
Nitro	Levo	TMS		ESBL		ESBL
Susceptibility	Susceptibility	Susceptibility	K. pneumoniae	K. pneumoniae	K. pneumoniae	K. pneumoniae
	lev	tms	9		20	2
nitro		RTMS		3	4	1
muo	RLEV	tms		1	1	3
		RTMS			1	2
	lev	tms	19	4	23	3
RNITRO		RTMS	1	3	2	4
RNITRO	RLEV	tms	2	3	1	6
	KLL V	RTMS	1	5		12

С

			Fos Sus	ceptibility	
Nitro Susceptibility	Levo Susceptibility	TMS Susceptibility	fos E. faecalis	RFOS E. faecalis	Quantity of isolates
	lev	tms	9		
nitro		RTMS	66	1	
	RLEV	RTMS	15	1	
RNITRO	RLEV	RTMS	1		

566

567 Figure 3. Numerical breakdown of the susceptibility patterns for all isolates tested. Columns depict the

number of isolates that are fosfomycin susceptible. Rows further delineate susceptibility to

nitrofurantoin, levofloxacin and TMS for E. coli, n=890 (A), K. pneumoniae, n=136 (B), and E. faecalis

- 570 n=93 (C). fos (fosfomycin susceptible), lev (levofloxacin susceptible), tms (trimethoprim and
- 571 sulfamethoxazole susceptible), nitro (nitrofurantoin susceptible). RFOS (fosfomycin non-susceptible),
- 572 RLEV (levofloxacin non-susceptible), RTMS (trimethoprim and sulfamethoxazole non-susceptible),
- 573 RNITRO (nitrofurantoin non-susceptible).





Figure 4. Global susceptibility of isolated strains to the antibiotics tested. Isolates were organized into

577 groups based on the number of antibiotics they were susceptible to. Non-ESBL *E.coli* strains were the


578 most susceptible to the antibiotics tested while ESBL *K. pneumoniae* strains were the least susceptible.

579 Dark purple indicates susceptibility to none of the antibiotics tested and gray indicates strains that were

580 susceptible to four antibiotics.




586



profiles of all isolates (n=1,119) tested were examined and profiles that had 10 or more isolates are


- 589 depicted here. The larger the circle the more isolates were in that group. fos (fosfomycin susceptible),
- 590 lev (levofloxacin susceptible), tms (trimethoprim and sulfamethoxazole susceptible), nitro
- 591 (nitrofurantoin susceptible). RFOS (fosfomycin non-susceptible), RLEV (levofloxacin non-susceptible),
- 592 RTMS (trimethoprim and sulfamethoxazole non-susceptible), RNITRO (nitrofurantoin non-susceptible).
- 593 Number of isolates for each profile included.



594

596

595 Figure 6. Distribution of fosfomycin MICs. MICs for fosfomycin were determined by E test for (A) E. coli,




(B) K. pneumoniae, and (C) E. faecalis.

601

600

603 Supplementary Figures



605 Supplementary figure 1. Susceptibilities of clinical isolates to fosfomycin and comparator antibiotics.

- 606 The agar dilution method was used to test whether clinical isolates were susceptible to fosfomycin.
- 607 Comparator antibiotic susceptibilities were tested using broth dilution. UTI isolates of E. coli (n=890), K.
- 608 pneumoniae (n= 136), and E. faecalis (n=93), P. aeruginosa (n=28), Citrobacter (n=26), P. mirabilis
- 609 (n=25), E. faecium (n=22), E. cloacae (n=20), K. aerogenes (n=19) were tested for susceptibilities to
- 610 fosfomycin and comparator antibiotics. *E. faecalis* was not tested for amoxicillin susceptibility and *E.*
- 611 *faecium* was not tested for nitrofurantoin, TMS, or amoxicillin susceptibilities.